Perhaps insurance companies would be quick to authorize and cover off-label Anavex2-73 prescriptions, once it was discovered, even in the absence of FDA approval, that it markedly stabilized or reduced Alzheimer's symptoms, thereby reducing subsequent medical costs for the insurance company.